Valion Bio (NASDAQ: VBIO) has shared the initial findings and priorities from Dean Zikria’s first 30 days as interim chief executive officer (CEO). Mr. Zikria’s strategic review has set a focused agenda built on three...
Inventiva (Euronext Paris and Nasdaq: IVA) is advancing development of an oral treatment for metabolic dysfunction-associated steatohepatitis (MASH) with its investigational next-generation pan-peroxisome proliferator...
Propanc Biopharma (NASDAQ: PPCB) has announced new preclinical research from an academic–industry collaboration from the Universities of Jaén and Granada, led by Dr. Maria Belén Toledo, that has identified the company’s...
Ironwood Pharmaceuticals (NASDAQ: IRWD) has announced the appointment of chief commercial officer Tammi Gaskins as CEO and a member of the board of directors, effective January 1, 2027. Current CEO Tom McCourt will...
Closely held PharmaJet has announced its participation in a pre-conference panel at the World Vaccine Conference Europe on October 19, 2026, at 14:15. Entitled From Non-Inferiority to Impact: Accelerating Adoption of...
TIME’s Best Innovations of 2026 includes a special mention of Perimeter Medical Imaging AI’s (TSX-V: PINK; OTCQX: PYNKF) Claire OCT System. Claire is the only FDA-approved imaging...
Valion Bio (NASDAQ: VBIO) and closely held LarmorBio today announced that Velocity Bioworks, Valion’s wholly owned biologics contract development and manufacturing organization (CDMO) subsidiary, has successfully...
Edesa Biotech (NASDAQ: EDSA) has announced that the FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment...
Claritev Corporation (NYSE: CTEV) has appointed Jennifer Main as a director of its board of directors, effective today, filling a newly created directorship on the board. Ms. Main brings more than three decades of...
Xenetic Biosciences (NASDAQ: XBIO) has announced that its collaboration partner, closely held PeriNess, has informed the company that the first patient has been dosed in an investigator-initiated clinical study...